Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Golodirsen→

Golodirsen PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1422959-91-8
FDA UNII
033072U4MZ
PubChem Substance Record
SID 377716578
Molecular formula
C305H481N138O112P25
Molecular weight
8,647.28 Da
Drug class
Antisense OligonucleotideOligonucleotides, AntisenseIncreased Protein Synthesis
Mechanism of action
Golodirsen is designed to bind to exon 53 of dystrophin pre-mRNA resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping.
Indications / reported uses
  • Muscular Dystrophy, Duchenne
  • Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping

Sources: FDA product labels (openFDA) · FDA product information

Identification sources: The FDA VYONDYS 53 prescribing information reports the molecular formula C305H481N138O112P25 and molecular weight 8,647.28 Da. The PubChem substance record (SID 377716578) and FDA GSRS record are included for cross-reference.

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Antisense Oligonucleotide; Oligonucleotides, Antisense; Increased Protein Synthesis

Mechanism of action

Golodirsen is designed to bind to exon 53 of dystrophin pre-mRNA resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping.

General use cases

  • Muscular Dystrophy, Duchenne
  • Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Golodirsen PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Golodirsen Permitted Daily Exposure (PDE) report (the Golodirsen PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Golodirsen Occupational Exposure Limit (OEL) report (the Golodirsen OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.